Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to confirm the non-inferiority of Tegoprazan 25mg, compared to
Lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis
confirmed by endoscopy following oral administration once daily(QD) for 6 months.